Maria Lowe, Ph.D., associate vice president of Pharmaceutical Intelligence at Institute for Clinical and Economic Review ...

Sarepta stock tumbled Thursday after European officials put all studies of the company's gene therapy, Elevidys, on hold.

Gene therapy companies have faced numerous setbacks over the last few years. What will it take for gene therapies to fulfill ...

Bain Capital’s Life Sciences team led the funding round, with contributions from new investor Wellington Management.

Head and neck cancers often begin in the mouth, throat, or voice box. They're among the most common cancers in the world, ...

Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the ...

In response to a request from the European Medicines Agency (EMA) following the death of a 16-year-old patient in the U.S., ...

Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing early investors to ...

Knocking out a single gene reprograms part of the large intestine to function like the nutrient-absorbing small intestine. In ...

None of the cell and gene therapies that reached the final regulatory submission stage were rejected by the FDA.

Neurona Therapeutics has circled up $102 million to push its off-the-shelf cell therapy for epilepsy through phase 3 testing.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved ...